Abstract
The newest centrifugal-flow (CF) left ventricular assist device (LVAD), the HeartMate 3 (HM3), has significantly lower rates of pump thrombosis. There is lack of literature regarding HM3 thrombosis in situ. A 55 year old man with an ischemic cardiomyopathy (LVEF 15%) and chronic idiopathic
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
